Abstract 5037
Background
Numerous investigations have been focused on the role of CXCR4, CCR2 and CCR5 in solid tumors, including breast cancer. These chemokine receptors make cancer cells move out of the circulation and traffic into organs with high amounts of chemokines, and thus forming metastases. In this connection, the objective of our stady was to investigate CXCR4, CCR2 and CCR5 expression in subsets of tumor cells with stem and/or EMT features in primary tumor and peripheral blood in breast cancer patients.
Methods
Twenty-three patients with breast cancer, between 29 and 69 years of age, were included in this study. Five-color confocal microscopy was used to investigate tumor cells with stem and/or EMT features, CXCR4, CCR2 and CCR5 expression in primary tumor. Flow cytometry was used to analyze the similar phenotypes of circulating tumor cells (CTC). All patients signed an informed consent for voluntary participation.
Results
In the primary tumor, CXCR4 was expressed on subsets of non-stem and stem-like tumor cells with EMT features. CCR5 was more often expressed by tumor cells with stem and EMT features. The count of such cells in the tumor decreased after neoadjuvant chemotherapy (NACT). CK7+CD45-CD44-CCR2+ and CK7+CD45-CD44-CXCR4+ CTC (without stem features) were detected in breast cancer patients with and without NACT. At the same time, the count of non-stem CXCR4+ CTC was significantly higher in the blood of patients after NACT. CK7+CD45-CD44-N-cadh+CCR5+ CTC (with EMT features) were more frequent in the blood of breast cancer patients after NACT, and its count was significantly higher. It is interesting to note that stem-like CTC didn’t express CCR2 and CCR5. Stem-like CXCR4+ CTC were rarely detected and had no EMT features in patients, regardless of the NACT performance. The count of CCR5+ tumor cells without stem and EMT features correlates with the count of non-stem CCR5+ CTC. The count of CXCR4+ tumor cells with stem and EMT features correlates with the count of non-stem CXCR4+ CTC with EMT features.
Conclusions
Thus, the potency for recruitment into the circulation is found in tumor cells with EMT features, regardless of the stemness status. The study was supported by the Russian Science Foundation (grant 19-75-30016).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3887 - First Real Life Data on Durvalumab after definitive concomitant ChemoRadiotherapy (cCRT) in unresectable Stage (St) III Non-Small Cell Lung Cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) Temporary Authorization of Use (ATU)
Presenter: Virginie Avrillon
Session: Poster Display session 1
Resources:
Abstract
682 - EGFR Inhibitor Versus Chemotherapy as Adjuvant Treatment for Locally-advanced EGFR-mutant Non-Small Cell Lung Cancer
Presenter: Peng Xie
Session: Poster Display session 1
Resources:
Abstract
2509 - Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3300 - First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Presenter: Daniel SW Tan
Session: Poster Display session 1
Resources:
Abstract
2653 - A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3663 - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients
Presenter: Xiaohong Wang
Session: Poster Display session 1
Resources:
Abstract
5921 - Definition of an afatinib trough concentration threshold in the treatment of NSCLC
Presenter: Stephane Bouchet
Session: Poster Display session 1
Resources:
Abstract
2852 - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)
Presenter: Beung chul AHN
Session: Poster Display session 1
Resources:
Abstract
3273 - Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer
Presenter: Jinsoo Lee
Session: Poster Display session 1
Resources:
Abstract
5141 - Mutational profiling of tumor tissue and sequential plasma illustrates emergent clones during treatment in late stage small cell lung cancer (SCLC)
Presenter: Stephanie Yaung
Session: Poster Display session 1
Resources:
Abstract